Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Summary of Significant Accounting Policies (Details Textual)

v3.7.0.1
Description of Business and Summary of Significant Accounting Policies (Details Textual)
1 Months Ended 3 Months Ended
Feb. 28, 2017
Mar. 31, 2017
Description of Business and Summary of Significant Accounting Policies (Textual)    
Dose escalation study description Patients will be administered Actimab-M on day 1 at an initial dose of 0.5 µCi/kg and then assessed at day 42 for safety and efficacy. The dose can be increased to 1.0 µCi/kg or reduced to 0.25 µCi/kg based on safety assessment that will evaluate dose limiting toxicities (DLTs). Patients may receive up to 8 cycles of therapy but in no event will cumulative administration exceed 4.0 µCi/kg of Actimab-M.  
Machinery and equipment [Member]    
Description of Business and Summary of Significant Accounting Policies (Textual)    
Estimated useful lives   Three years
Property and equipment depreciation method   Straight-line basis
Furniture and fixtures [Member]    
Description of Business and Summary of Significant Accounting Policies (Textual)    
Estimated useful lives   Three years
Property and equipment depreciation method   Straight-line basis